SPACs in Biopharma: Boom or Bust?

May 27, 2021 11:00 AM - 11:45 AM

Webinar, click "live-stream" button to view

Add to Calendar 5/27/2021 11:00:00 AM 5/27/2021 11:45:00 AM SPACs in Biopharma: Boom or Bust?

2020 saw a special purpose acquisition company (SPAC) boom in the life sciences industry: 33 biopharma SPACs raised more than $6B globally. Now halfway into 2021, SPACs continue to show promise as a new way for emerging biopharmas to go public, but are they living up to the early hype?

In this virtual Forum, panelists will share their bullish or bearish thoughts on the recent surge in SPACs. Topics will include:

  • The SPAC investment ecosystem
  • Pros/cons about launching via a SPAC
  • Navigating SPAC investing
 Webinar, click "live-stream" button to view
Principal, EcoR1 Capital, LLC
Mr. Platshon joined EcoR1 Capital, LLC in October 2015 after spending a year at Aquilo Partners, a boutique life sciences investment bank. Alongside Ms. Stout, Mr. Platshon serves as an analyst and is responsible for due diligence and analysis of biotechnology companies for value-oriented investment opportunities. At Aquilo, Mr. Platshon prepared valuation materials and performed due diligence on M&A, licensing, and private placement transactions in the biotech, pharmaceutical and tools & diagnostics sector. Mr. Platshon holds a Bachelor of Science in Bioengineering from Stanford University, and was advised by Karl Deisseroth, the inventor of optogenetics and CLARITY, two breakthrough neuroscience technologies.